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Abstract
Introduction: The molecular mechanism underlying mitochondrial BAK activation during apoptosis remains highly
controversial. Two seemingly conflicting models have been proposed. In one, BAK requires so-called activating BH3 only
proteins (aBH3) to initiate its conformation change. In the other, displacement from inhibitory pro-survival BCL-2 proteins
(PBPs) and monomerization of BAK by PBP selective dissociator BH3-only proteins (dBH3) is sufficient.
Methodology/Principal Findings: To better understand the kinetic implications of these conflicting but highly evidence-
based models, we have conducted a deterministic, dynamical systems analysis to explore the kinetics underlying the first
step of BAK activation, as a non-linear reaction system. We show that dBH3 induced BAK activation is efficient, even in the
absence of aBH3s, provided constitutive interaction of PBPs with open conformation BAK occurs in an adenoviral E1B 19K-
like manner. The pattern of PBP expression robustly predicts the efficacy of dBH3s.
Conclusion: Our findings accommodate the prevailing BAK activation models as potentially coexisting mechanisms capable
of initiating BAK activation, and supports a model based approach for predicting resistance to therapeutically relevant small
molecule BH3 mimetics.
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Introduction
Resistance to apoptosis is a hallmark of cancer and a pivotal
factor underlying resistance to systemic anti-cancer therapy.
Multidomain proapoptotic BCL-2 family proteins BAX and
BAK are genetically redundant tumour suppressors and central
regulators of apoptosis [1,2]. BAK is a zinc regulated protein, and
is constitutively localized to the outer mitochondrial membrane
[3–5]. At least three steps are involved in BAK activation. The first
step, involves a conformation change associated with exposure of
the N-terminus. The second involves deep insertion into the outer
mitochondrial membrane at the C terminus [6], and the third,
oligomerization into a complex of as yet unknown stoichiometry
leading to outer membrane permeabilization [7]. BAK auto-
activation may drive this reaction forwards once initiated [8].
BAK oligomers cause mitochondrial outer membrane permeabi-
lization (MOMP) by an unknown mechanism, leading to release of
apoptogenic factors and activation of caspase dependent and
independent events that in parallel, promote cell death. Once
initiated, BAK mediates loss of the mitochondrial membrane
potential that is required for oxidative phosphorylation, a
reduction in cellular ATP level, and caspase independent cell
death. Feedback mechanisms driven by caspases following MOMP
also inhibit electron transport, ensuring cessation of respiration.
Consequently, BAK activation when initiated causes a series of
irreversible events that commit the cell to death.
BAK is activated by a subclass of proapoptotic BCL-2 proteins
which share an amphipathic alpha helical BH3 domain (BH3-only
proteins) [2,5]. However, there currently exists considerable
controversy as to how this activation occurs. Two seemingly
irreconcilable models have been described. In the agonism model,
a subclass of activator BH3-only proteins (aBH3s) comprising BID,
BIM and arguably PUMA, interact with a putative activation
binding site analogous to BAX [9,10], leading to a conformation
change and oligomerization [11–13]. Such activators may be
constitutively bound to mitochondrial pro-survival BCL-2 family
proteins such as BCL-2, or MCL-1. Under such conditions,
described as ‘‘priming for death’’, a second class of dissociator
BH3-only proteins such as BAD or NOXA (dBH3s) can release
activators to engage BAK [2,14,15]. This hierarchical BH3
regulation may underlie the activity of such small molecule
dissociator BH3 mimetics such as ABT737 [15] or obatoclax [16].
It is the selectivity of dBH3s for their recognized pro-survival BCL-
2s that determines BAK activating efficacy [17]. For example,
coordinate restraint of BAK by BCL-XL and MCL-1 can be de-
repressed by BAD and NOXA together, but not individually [18].
BAK is neutralized by BCL-2, BCL-XL, MCL-1 or VDAC2
[19,20] and can be activated by the small molecule BAD BH3
PLoS ONE | www.plosone.org 1 August 2008 | Volume 3 | Issue 8 | e3038mimetic ABT737, in the absence of aBH3s [21,22]. This has led to
the hypothesis that direct aBH3 dependent agonism is not essential
for BAK activation, but that antagonism of pro-survival BCL-2
family proteins alone is sufficient [21]. This is the second
conflicting model of BAK activation.
Pure agonism versus de-repressor models reflect contrasting
thermodynamic representations of BAK regulation. In the
agonism model, BAK’s requirement for ligand driven conforma-
tion change suggests an intrinsic energy barrier or activation
energy that prevents spontaneous activation, and must be
surmounted. This is facilitated by the agonist in a catalytic-like
manner. A corollary of this model is that BAK should be capable
of residing in a stable inactive monomeric conformation, until
bound by its agonist ligand. In direct contrast, the de-repressor
model suggests that BAK will spontaneously unfold its N-terminus
unless a constitutive repressor is bound. Release of BAK by dBH3s
will then cause its activation.
Because these scenarios are in conflict, we have employed a
deterministic mathematical modelling strategy to explore the
concentration-dependent effects of aBH3 and dBH3s alone or in
combination, on the maximum rate of BAK activation. Our
findings suggest that both the agonism and dissociation models
reflect valid and potentially coexisting mechanisms for BAK
activation, provided that strict constraints are applied.
Results
Mitochondrial BAK activation by an aBH3 domain
The solutions for the simplest BAK activation model involving a
bimolecular reaction between b1 (aBH3 domain) and B (BAK) to
yield B* (open conformation BAK), is defined by four linear first
order differential equations (figure 1A), and yields graphs of the
change B, b1, b1.B, and B* with time (figure 1B). B* exhibits a
rapid initial rise and tends to a plateau corresponding to the
maximum output, B*max. Accordingly, B is consumed by the
reaction as B* is formed. The transition complex B.b1 exhibits a
transient increase in level, which reduces to zero as it converts to
B*.b1 and dissociates to B* and b1. Free b1 initially declines in
level as it is consumed into B*.b1, but increases upon dissociation
from its complex with B*, becoming free again to participate in
further reactions until all available B is been converted to B*
(figure 1B).
Solving the dynamical system with seven iterations over a six log
fold range of b1 ratio, yields different values of Bmax and a
sigmoidal concentration response (figure 1C), such that B*max
increases to a limit. The ratio of b1 is given by the ratio of 0.001,
0.01, 0.1, 1,10,100 or 1000 to the initial value 1610
9 M and is
therefore dimensionless. The concentration-response curve is
estimated by fitting the logistic function, and yields parameter
estimates of M=19.48 (95%CI=18.62 to 20.34) , l=2.95
(95%CI=2.22 to 3.92), and p=1.71 (95%CI=1.30 to 2.11).
The logistic function provides a good fit to the log b1
concentration-B*max curve, with R
2=0.997
A decrease in the affinity of b1 for B, DKD (reducing from a
high value of 100 to 10) produces a corresponding decrease in the
potency of b1, such that both the maximum achievable output of
the system, and ratio producing half maximal output, are
significantly reduced. The plateau parameter estimated by
regression reduces from 20 (95%CI=19.82 to 20.18 for
KD=10 610
29 M) to 5.63 (95%CI=5.12 to 5.42 for
KD=0.1610
29 M). The estimated l reduced from 12
(95%CI=10.71 to 13.47) to 0.2 (95%CI=0.17 to 0.24) with
increasing affinity. This is consistent with the dramatic increase in
BH3
BID efficacy observed experimentally, when the alpha helix is
stabilized by olefin metathesis and all-hydrocarbon stapling
[13,23]. An increase in the amount of available B in the reaction
(DB), from 10 to 100 also results in a corresponding change in
B*max (figure 1E). The M parameter estimated by regression
increases from 9.50 (95%CI=9.28 to 9.71 for B=10) to 95
(95%CI=91.05–99.70 for B=100). Consequently, the rate of B*
generation by b1 is critically dependent on the amount of B in the
system consistent with the observed loss of efficacy of BH3
domains in the absence of BAK (and BAX) [2].
Regulation of B* kinetics by Pro-survival BCL-2 proteins
and reversal by dBH3s
Introducing a single prosurvival BCL-2 protein (A1) results in
the reaction scheme (where the A1 targeting dBH3, b21=0) and
system of differential equations shown in figures 2A and 2B
respectively. As A1 ratio increases over a 6 logfold range, B*max
reduces, exhibiting bistability with a steep fall in B*max production
towards zero at higher A1 concentrations (figure 2C). Therefore,
the presence of A1 per se does not necessarily suppress b1 driven
B* formation, however, above a certain threshold level, the
production of B* will rapidly switch off, causing complete
resistance to b1. This property is consistent with the rheostat
model originally described in relation to BAX/BAK by Kors-
meyer and colleagues [24].
At maximum A1 ratio (A1max=10), this is associated with
complete suppression of B* production. However when the dBH3
b21 is introduced, and increases, B* production is efficiently de-
repressed, achieving B*max close to that in the absence of A1 at
b21max=10 (plateau parameter estimate, M=19.48 (95%
CI=18.62 to 20.34 for A1=0, b21=0) compared with
M=18.61 (95%CI=18.41 to 18.82 for A1=10, b21=10,
figure 2D). Accordingly, where a dominant prosurvival protein is
expressed above critical threshold concentrations required to
efficiently suppress B*max, a dBH3 domain targeting A1, can de-
repress the system allowing near full activation of B when the
stoichiometric ratio of b21:A1 approaches reaches 1.
BAK antagonism by two prosurvival BCL-2 family
proteins requires a second type of dBH3 to enable
activation
Although the suppressing effect of A1 on B*max is efficiently
reversed by b21, introducing a second prosurvival BCL-2 family
protein, A2 which binds b1 but does not interact with b21 results
in the reaction scheme and system of differential equations shown
in figures 3A and 3B. With increasing A2 ratio in the presence of
A1max and b21max,B * max reduces, albeit with a less steep decline
compared to that of A1 alone (slope parameter, p=21.23
(95%CI=21.31 to 21.24, compared with p=21.53
(95%CI=22.10 to 20.96 for A1max,A2max,b21max. However,
complete suppression is still achieved as A2 tends towards a
maximum effective ratio (A2max=10), as shown in figure 3C.
Introduction of a second BH3 domain (b22) which interacts
selectively with A2, can efficiently de-repress B* formation in the
presence of A1max/b21max and A2max. The maximum output
achievable by b21 (at b21max=10) is the same as that even in the
absence of either A1,A2,b21o rb 22 (M=20.1 95%CI=19.84 to
20.17)
BAK activation kinetics in the absence of aBH3
Recent genetic evidence supports an activation model for BAK
which does not require the presence of aBH3s (BID, BIM or
PUMA) [18,21]. This suggests that overcoming an activation
energy for conformation change of BAK is not required, rather,
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lower energy state. In the dynamical systems model, B therefore
requires restraint by PBPs A1 and A2 , which can co-ordinately
bind B into two kinetic compartments, namely B.A1 and B.A2
(figure 4A). However, since the transition BRB* is assumed to be
essentially irreversible, and the interactions of B with A1/A2 are
assumed to be reversible, this model is highly unstable with B*
forming spontaneously, relatively slowly over time (figure 4B).
Figure 1. Modelling the outer mitochondrial membrane bimolecular collision between and activating BH3 peptide and BAK. A)
Reaction scheme showing the interaction between b1 and B leading to formation of a transition complex, and its dissociation to free open BAK (B*)
and recycled b1. Below is the corresponding system of differential equations corresponding to this system. B) Graph showing the timecourse of
changing concentration of species following an instantaneous concentration jump in b1. Note, B* tends to a plateau, B*. C) Concentration response
relationship for log b1 ratio vs B* as an iterative solution to the corresponding system of equations. D) Graphs showing the dependency of b1
potency on the affinity of b1 for B E) Graph of log b1 ratio against B*; the concentration of B has a significant influence on the maximum activity of
b1.
doi:10.1371/journal.pone.0003038.g001
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with BAK in its open conformation [8]. In the dynamical system
where B and B* interact with A1/A2 (figure 4C), the system is
stable, and A1/A2 can suppress free B* formation (figure 4D).
Under these conditions, de-repression of bound B and B* can be
achieved by addition of b21 with or without b22 (figure 5A).
Together b21 and b22, when varied with the same concentration
ratio, are more effective in freeing B* than b21 alone leading to a
higher B*max at increasing concentration ratio (M=20
95%CI=19.98 to 20.02 for b21 alone), compared with M=40
(95%CI=39.80 to 40.92 for b21 and b22, figure 5B).
BAK activation by an aBH3 is enhanced by dBH3s when
PBPs inhibit open BAK
Since binding of B* to A1 with or without A2, is essential for
stable suppression of B* in the absence of b1, this mechanism can
be incorporated into a dynamical system that includes b1 driven
opening of B, with B* binding by A1/A2 (figures 6A and 6B).
Under these conditions, b1 in the presence of b21 results in
activation of B* even though A2 is present, however the maximum
output of the system is the same as for b21 activity in the absence of
b1 shown in figure 5C (ie. M=19.02 95%CI=16.66 to 21.37 in
the presence of b1). Note, B* production is zero when b21=0 and
b22=0 in this system since spontaneous B* is not assumed to occur.
When b22 is added to the system, b1 efficacy is enhanced with a
decrease in the EC50 with l reducing from 8.4 (95%CI=4.86 to
14.63 for b21 only), to 3.12 (95%CI=0.62 to 15.80 for b21 plus
b22). In contrast, the maximum output of the system remains
approximately constant with M=21.9 (95%CI=15.65 to 28.04
for b21 plus b22) compared with M=19.02 (95%CI=16.66 to
21.37 for b21 only). Accordingly, b21 and b22 enhance b1 efficacy,
resulting in left shift of the concentration response relationship, but
with reduced maximum B* production, compared with the system
in which b1 is absent.
Figure 2. Modelling the antagonism of an activating BH3 domain by a single prosurvival BCL-2 protein, and its de-repression by
addition of a dissociating BH3 domain. A) Reaction scheme showing the interaction between A1, b21, b1 and B. In this reaction, A1 binds to b1.
B) The corresponding system of differential equations corresponding to this reaction scheme. C) Graph showing the reduction in B* with increasing
A1 ratio. D) Concentration response relationship for log b21 ratio vs B* as an Iterative solution to the corresponding system of equations.
doi:10.1371/journal.pone.0003038.g002
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presence of the aBH3 in a unified model
As previously shown, in order for dBH3s to be able to generate
B* in the absence of b1, spontaneous activation of B* must be
assumed, with constitutive binding of A1/A2 to B*. Accordingly
formation of B* would occur via two simultaneous pathways, one
driven by b1, the other by derepression of spontaneously formed
B*. Since the prevailing models of BAK activation suggest that
each are equally possible, both activation pathways can be
combined in a unified model (figure 7A and 7B).
The plot of log b1 ratio against B*max in the presence of b21
(figure 7C) shows that b21max alone in the presence of A1max and
A2max can induce the low level production of B* when b1=0.001
(the level of B*max is 5.0, 95%CI=4.63 to 5.30), however addition
of b1 across a 6 logfold range, increases B* production in a
concentration dependent manner tending to a maximum
(M=17.84, 95%CI=16.88 to 18.80). When b22 is added to
b21, B* production by b1 is increased slightly , leading to a higher
maximum output (M=19.9, 95%CI=19.94 to 20.01). The initial
level of B* production (at b1=0.001) is also higher than for b21
Figure 3. Modelling the antagonism of an activating BH3 domain by a second prosurvival BCL-2 protein, and its de-repression by
addition of a second dissociating BH3 domain. A) Reaction scheme showing the interaction between A1, A2, b21, b22, b1 and B. In this
reaction, A1 and A2 bind to b1. B) The corresponding system of differential equations corresponding to this reaction scheme. C) Graph summarizing
the iterative numerical solutions of the corresponding system of differential equations, showing the reduction in B* with increasing A2 ratio at
maximum A1 and b21. D) Concentration response relationship for log b22 ratio vs B* as an Iterative solution to the corresponding system of
equations in the presence of maximum concentration of A1, A2 and b21.
doi:10.1371/journal.pone.0003038.g003
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system is similar to that of b21/b22 in the absent b1 model shown in
figures 4–5, but greater than the agonistic models described in
figures 1–3. From the unified model, it is clear that b22 and b21 are
required to enable maximum potency of b1 when both A1max and
A2max are present. Somewhat paradoxically however, the presence
of b1 limits the maximum output achievable by the dynamical
system by around 50% compared with the absent b1 model
(figures 4 and 5).
Discussion
We have used dynamical systems analysis to explore the kinetics
of mitochondrial BAK activation in the presence or absence of
Figure 4. Activation of BAK in the absence of an activating BH3 domain. A) Reaction scheme showing the coordinate antagonism of B* by
A1 and A2 in the absence of b1. Binding to B only is shown. The corresponding system of differential equations are shown below. B) Plot of B*
showing the inherent instability of this system over time. C) Modified reaction scheme with b1=0 in which B* is now bound by A1. The system
includes b21 and A2. D) As A2 increases, B* formation is increased in the absence of b1.
doi:10.1371/journal.pone.0003038.g004
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induce apoptosis at the level of the outer mitochondrial
membrane. Mathematical modelling enables deeper insight and
understanding of complex dynamic systems [1,2]. However, there
have been no attempts to date to model mitochondrial membrane
resident BAK in the context of multiple PBPs nor multiple dBH3s,
which are both biologically relevant. In silico modelling has been
reported in relation to BAX , however these studies were limited to
considerable simplification of the interactions between one PBP,
aBH3 and BAX, and have attempted to incorporate both
mitochondrial translocation of BAX/aBH3 and outer mitochon-
drial permeabilization events, both of which are poorly defined at
the molecular level [25,26]. Furthermore, BAX/BAK are resident
in the endoplasmic reticulum as well as the mitochondrial
compartment, and probably behave as interacting dynamical
systems. For example, the BH3 only proteins BIK triggers ER
BAK leading to ER-mitochondrial interactions and apoptosis
[27,28].
Figure 5. Effect of two dBH3 domains: Open BAK restrained by two-prosurvival BCL-2 proteins in the absence of a aBH3 peptide. A)
Reaction scheme showing the interaction between A1, A2, b21, b22, and B in the absence of b1. In this reaction, A1 and A2 bind to b1, B and B*. B)
The corresponding system of differential equations associated with this reaction scheme. C) Graph of the iterated solutions of the corresponding
system of equations at varying b1 showing the relative effects of b21 with or without simulanteous variation in b22 across a three log-fold range, on
B*.
doi:10.1371/journal.pone.0003038.g005
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complex than that which has been previously mathematically
modelled, even at the level of the mitochondrial membrane alone,
by virtue of their heterogeneity. Cancer cell models commonly
harbour constitutively expressed BAK and multiple PBPs (these
may include BCL-2, BCL-XL, MCL-1, A1 and BCL-W
coexpression in the case of non-small cell lung cancer – data
unshown). Furthermore, so-called priming for death involves
mitochondrial co-expression of BH3s (aBH3s and dBH3s) which
have translocated constitutively and are neutralized by PBPs
[29,30]. Membrane bound BAK activation and engagement with
PBPs and BH3s takes place in a single spatial compartment,
potentially enabling more robust and accurate models of BAK
activation by a BH3 domain peptide to be defined. We have
therefore focused on a reduced but experimentally testable system
that explores the interaction of BH3 domains at the isolated
mitochondrial surface, which has been shown to conserve
functional BAK.
Figure 6. Effect of two dissociating BH3 domains: Open BAK restrained by two-prosurvival BCL-2 proteins in the presence of an
activating BH3 peptide. A) Reaction scheme showing the interaction between A1, A2, b21, b22, B in the presence of b1. In this reaction, A1 and A2
bind to b1, B and B* and are at maximum concentration of 10 nM. B) The corresponding system of differential equations associated with this reaction
scheme. C) Graph of the iterated solutions of the corresponding system of equations, showing log b1 ratio versus B*; b21 effectively derepresses the
system enabling B* output, and addition of b22 further enhances b1 potency, causing a shift of the concentration-response curve to the left.
doi:10.1371/journal.pone.0003038.g006
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mitochondrial BCL-2 proteins and BH3 domains, although
complex, are amenable to this mathematical modelling approach.
A considerable body of evidence has amassed implicating aBH3
domains as being capable of triggering multidomain BCL-2 family
protein activation [11,12,17]. Putative activating residues in BAX
have been proposed through mutational analysis [9] and
stabilization of BH3 domains using all hydrocarbon stapling has
demonstrated the activating ability of BID BH3 domain [13]. The
ability of aBH3s to drive BAK conformation change and
oligomerization strongly suggests that as yet unidentified trigger
residues also resides in BAK. Because mitochondria can be
isolated, and respond to aBH3 peptide domain in a manner
observed in vivo [11,12], our model incorporates a rapid (near
instantaneous) concentration jump of aBH3, leading to initiation
of the reaction leading to B*. This is consistent with pharmaco-
logical exposure in a cell free system, and is relevant to modelling
the action of small molecule BH3 peptidomimetics [15].
Figure 7. Unified model incorporating both b1 driven and spontaneous activation of B. A) Reaction scheme showing the interaction
between A1max,A 2 max,b 21, b22, B in the presence of b1. In this reaction, A1 and A2 bind to b1, B and B* and are at maximum concentration of 10 nM.
B bifurcates in its activation with equal probability leading to either spontaneous activation or b1 driven activation. B) The corresponding system of
differential equations associated with this unified reaction scheme. C) Graph of the iterated solutions of the corresponding system of equations,
showing log b1 ratio versus B* for b21 alone or b21 plus b22.
doi:10.1371/journal.pone.0003038.g007
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clearly identify constitutively monomeric BAK in the outer
mitochondrial membrane [8]. BMH internally crosslinks BAK
cysteine residues 14 and 166, leading to a fast mobilizing band on
SDS PAGE. This fast band reflects within-membrane, closed
conformation BAK, and is lost in the presence of BID BH3 peptide,
consistent with unfolding and activation at the level of a monomeric
species. The existence of closed conformer BAK in the outer
mitochondrial membrane of healthy isolated mitochondria also
implicates a constitutively left-shifted equilibrium strongly towards a
closed/inactive conformation. Therefore, a requirement for consti-
tutive PBP repression alone in this compartment is unlikely. If BAK
can reside in the outer mitochondrial membrane as an inactive
monomer, collision with an aBH3 would be required for activation.
This model is entirely inconsistent with BAK requiring constitutive
repression only to prevent its activation as suggested from genetic
studies [18,21]. Conversely, robust genetic evidence has confirmed
that BAK activation can proceed in the absence of known aBH3s,
suggesting that in some systems, constitutive BAK-PBP interaction
is necessary to prevent its activation.
This raises the important question of how two seemingly
contradictory models can be reconciled. Dynamical systems
analysis provides a powerful tool to capable of providing
important insights to explain these experimentally observed
phenomena. Our results strongly suggest that stable complexes
of BAK can only occur in the open conformation (B* as opposed
to B), and that disruption of complexes with PBPs will yield free
B*, which is assumed to be capable of further activation (deep
membrane insertion, oligomerization, and autoactivation). B*
binding is observed for adenoviral E1B19K and BCL-2 . A central
paradox in this model, is how B* forms in the first place, when no
aBH3s are present (ie. in genetic knockouts). This may be
explained in at least two ways. Firstly, unknown death signals may
be capable of driving BAK conformation change in the absence of
the known aBH3s BID, BIM and possibly PUMA. Secondly,
conversion of B to B* may happen spontaneously, albeit with
much lower probability compared with aBH3 driven conversion.
In the absence of aBH3s therefore, pro-survival BCL-2 proteins
would therefore provide an efficient safety mechanism for
blocking BAK activation after it has undergone its conformation
change.
An important question relates to the fate of B* upon release
from its complex with either A1 and/or A2 by b21 and/or b22. B*
can autoactivate other B molecules to form oligomers. Further-
more, b1 which is also freed from A1 and/or A2 is then capable of
causing ballistic conversion of B to B* in the outer mitochondrial
membrane. What is clear from experimental studies, is that the
pharmacological characteristics of BH3 domains differ significant-
ly. Therefore, BH3
BAD and BH3
NOXA although able to sensitize
BH3
BID, does not mimic this aBH3 [11,12].
The systems of equations solved for the reaction schemes
described here, consider only the first step in the activation of
BAK. Free open conformation BAK may nucleate other closed B
molecules, through an autoactivation [8]. Auto-activation would
therefore be expected to dramatically increase the kinetics of free
B* formation. Furthermore, auto-activation may result in
nucleation of newly activated Bs into a multimeric B* complex
following homo-oligomerization [7]. The mechanisms and kinetics
of BAK oligomerization are poorly understood. MOMP can occur
within minutes of exposure to BH3 peptide or full length protein,
however the minimal stochiometry of the molecular apparatus
responsible for MOMP is as yet undetermined. The electrophys-
iologically detectable mitochondrial apoptosis channel comprises
BAX and BAK, and may require other proteins for assembly
[31,32]. For example, a recent report implicates the TOM
complex in the process of MOMP. Assembly of the outer
membrane pore may proceed ballistically and without limit,
leading to the observale BAX/BAK clusters previously
reported [7].
The modelling described, assumes stable levels of the interacting
molecules over time. It is known that antiapoptotic BCL-2s such as
MCL-1 can undergo marked changes due to proteosomal
degradation [21] following its dissociation. As such, the influence
on b22 on A2 could in some systems increase the non-linearity of
the system due to alterations in A2 level with time as well as
dissociation from B*, B and b1.
Our results demonstrate that the selectivity of binding of BH3
only proteins to their PBP counterparts in the outer mitochondrial
membrane, clearly has a major impact on B*. The ability of
dBH3s and small molecule BH3 peptidomimetics to free B* should
therefore be associated with significant proapoptotic pharmaco-
logical activity, in a manner that is not significantly influenced by
the expression of aBH3s in cancers. Resistance to dBH3 domains
or peptidometics will therefore depend on the expression pattern
of PBPs. The shape of the b21/b22 concentration response curves
suggests that A1 and or A2 expression above a critical level is
essential to efficiently suppress B*. This has implications for
resistance biomarker screening. For example, the BH3 peptido-
mimetic ABT737 is inhibited by overexpression of MCL-1,
consistent with its BAD like binding selectivity to BCL-2/BCL-
XL/BCL-W. However, our modelling predicts that MCL-1 levels
below a threshold of expression and not MCL-1 expression per se,
should dictate resistance to BAD-like peptidomimetic induced
apoptosis.
We have examined the predicted behaviour of unified system in
which both spontaneous BRB* generation occurs resulting in a
pool of A1/A2 inhibited B*, and also b1 driven BRB*. In this
model, as expected b1 achieves a concentration dependent
increase in B*max, however, somewhat paradoxically, the presence
of b1 limits the magnitude of Bmax that is achievable in the unified
model. Cancer cells have been shown to spontaneously process
aBH3s, which are neutralized at the mitochondrial surface
accounting for the so-called priming for death phenomenon. With
respect to opening of BAK, which alone is not sufficient to induce
MOMP, b1 is predicted from the unified model to reduce the
amount of B*. One might anticipate that the selection pressure
that leads to the antiapoptotic phenotype in cancer might reduce,
not increase the mitochondrial priming for death with aBH3
tumour suppressors. The unified model, provides a potential
explanation for this experimental observation and suggests that
this phenomenon effectively limits the maximum BAK activation
achievable by dBH3 induced B*max. Conversely, elimination of
primed aBH3s, might be expected to enable higher B*max in
response to dBH3s. Nevertheless, where b1 is present in a system,
addition of dBH3s will potentiate b1 mediated B* activation,
consistent with experimental observation and therefore strongly
supports the use of BH3 peptidomimetics as potential as
anticancer agents.
In summary, dynamical systems analysis of BAK activation
reconciles and supports a general model in which the interplay
between BAK, and multiple PBPs determine susceptibility to
dBH3 domains (and therefore mimetics such as ABT-737 and
GX15-070), in both the presence or absence of an aBH3. As such,
this approach has implications for better understanding of the
complex molecular mechanisms that underlies BCL-2 family
addiction, the implications of mitochondrial priming for death, as
well as critical factors governing sensitivity or resistance to BH3
peptidomimetics now entering the clinic.
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BAK activation by a BH3 agonist
A one dimensional deterministic system was established to
model the rate of BAK activation in the mitochondrial outer
membrane according to the agonism model. The diffusion path of
BAK is constrained to the plane of the outer mitochondrial
membrane where it has been proposed to directly interact with
aBH3 domains. When an aBH3
BID is applied to isolated state IV
mitochondria, BAK is rapidly converted from a closed monomeric
form to an open form, as evidenced by loss of an internally
crosslinked species due to lack of bismaleimeidohexane cross-
linking between cysteines 14 and 166 [8]. Applying the the law of
mass action to the bimolecular collision of an aBH3 domain (b1)
with BAK, hereafter referred to as B, enables the forward reaction
rate associated with the first step of BAK activation (B*) to be
determined. It is assumed that an instantaneous b1 concentration
jump initiates formation of B*, consistent with addition of an
exogenous aBH3 or dBH3 domain peptide to isolated mitochon-
dria. B is assumed to be constitutively monomeric, immediately
prior to collision with b1.
B and b1 are assumed to form a transition complex (B.b1). B
then undergoes transition to its open conformation, B*. The
complex B*.b1 is assumed to have a very short lifetime, reflected in
observed ‘‘kiss-and-run’’ BID and BAX [13]. It is therefore
assumed that the transition B.b1RB*.b1 is sufficiently rapid to
justify simplification by encompassing B.b1RB*.b1 into the single
reaction B.b1RB* + b1, with the associated conformation change rate
coefficient k+2. It is assumed that recycling of free b1 follows
dissociation of B.b1, enabling its re-use in subsequent interactions
and ballistic B* generation.
Modelling multiple Pro-survival BCL-2 protein
interactions and their antagonism
Prosurvival BCL-2 family proteins (PBPs) A1 or A2 interact
with b1 preventing its binding to B to yield B*[30]. PBPs can also
interact with B and B* [8,30]. In turn, A1 and A2 exhibit selective
interactions with the dBH3s b21 and b22, which displace b1 from
A1/A2 to form the stable complexes b21.A1, and b22.A2
respectively. The interaction of A1 with b21 is analogous to to
the selective binding of BH3
BAD to mitochondrial BCL-2, BCL-
XL or BCL-W, whereas the A2 interaction with b22 corresponds
to the interactions of MCL-1 or A1 with with BH3
NOXA. For the
purposes of simplification, the variables A1 and A2 can be
considered to represent functionally redundant pools of mito-
chondrial PBPs with identical stoichiometry, affinities and effects
on B* kinetics, whereby, A1 corresponds to BCL-2, BCL-XL,
BCL-W and A2 corresponds to MCL-1/A1.
Modelling BAK activation in the absence of an agonistic
BH3
The rate of B* generation under conditions where b1=0,
corresponds to the recently reported double BID/BIM knockout
plus PUMA knockdown model system [18,21]. By removing b1
from the system, the effect of b21 with or without b22 on expressed
A1, with or without A2 can be examined, solving for B*.
Computational Modelling
It is assumed that BAK activation kinetics can be analyzed using
classical reaction kinetics and application of the law of mass action.
The variables B, A1, A2, b21, b22 are initially constant until
introduction of b1 as an instantaneous concentration jump. The
reactants are assumed not to exhibit significant changes in
concentration, which might be due to either synthesis or
degradation over the timescales of interest. Systems of ordinary
differential equations corresponding to different reaction schemes
were solved numerically using MATLAB (Mathworks, Massachu-
setts) ODE solvers on personal desktop computer installed with the
Linux operating system. For simplification, all equilibrium
dissociation rate constants (ratio of association to dissociation rate
constants) are set to 1610
29 M. This reflects the order of
magnitude of binding affinities for dBH3 domain-PBP interactions
reported using surface plasmon resonance measured under ex vivo
conditions [17] and novel BH3 peptidomimetics such as ABT-737
[15]. Initial concentrations of all reactants are assumed to be
1610
29 M. The simplified conformation change rate constant k2
corresponding to combined BRB* transition and dissociation of
B*.b1 is unknown but is assumed to be 1610
26 S
21 corresponding
to an efficient enzyme catalytic rate (http://doqcs.ncbs.res.in/).
In the dynamical systems described, the effect of varying the A1,
A2, b21o rb 22 ratio across a 6 logfold range [10
23,1 0
3] on the
maximum output of the system (Bmax) are determined graphically,
through iterative solving of the corresponding system at varying
concentrations of b1 or other specified variable. The denominator
of the concentration ratio is taken to be 1610
9 M for all reactants,
the numerator being the logfold multiples of this value (106,
1006, or 0.16, 0.016 etc). As such, concentration-response
relationships can be generated (over seven iterations), under
conditions which correspond to the presence or absence of A1/A2
with or without b21/b22 in the presence or absence of b1. Where
indicated, the effect of A1, A2 or b1 is estimated as the log
concentration ratio producing half maximal reduction or increase
in B* respectively (EC50) estimated by non-linear regression. The
inverse logistic function is used to estimate EC50 for A1/A2 and
corresponds to the equation:-
y ~ 1 {
xp
l
p z xp

where l estimates the EC50 and p is the Hill-slope of the curve; the
logistic function for analysis of the b1 concentration response
relationship is given by the equation:-
y ~
Mxp
l
p z xp
where M is the plateau estimator. Curve fitting employed the
GraphPad Prism non-linear regression application (La Jolla). All
parameter estimates from non-linear regression are shown with 6
approximate 95% confidence limits.
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